Given the importance of THR-β in NASH, other THR-β agonists such as VK2809 (NCT04173065), ALG-055009 (NCT06342947), HSK31679 (NCT05795517) have been developed, all of which are currently under clinical evaluation. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.